IL6 and rheumatoid arthritis: In addition, ABT-122 can quickly alter the potential pathophysiological pathways of RA patients (including reducing the chemokines CXCL9, CXCL10, and CCL23) and completely inhibit the production of IL-6 induced by TNF-α and IL-17A (109–111).